Cell Signaling and Metabolism: Bridging a Gap in Cancer Therapies from thescientistllc on Vimeo.

That cancer cells display an altered metabolism has been known for almost a century, but the cell-signaling mechanisms responsible for this phenomenon are just beginning to be understood, with some drugs targeting key regulators of both cell metabolism and tumor progression. The repurposing of old drugs for the activation and/or inhibition of proteins at the center of the cell-signaling and metabolism web has been a popular strategy for addressing these challenges. Drugs like metformin, chloroquine, and various statins are just a few examples of those in clinical trials. They offer a cost-effective advantage in addition to an already-established pharmacokinetic and pharmacodynamic profile. To further explore cell metabolism as a novel avenue of drug discovery based on already-established cell signaling mechanisms essential for tumor progression, The Scientist is bringing together a panel of experts to discuss...

Topics to be covered:

  • Metabolic symbioses in tumor microenvironments
  • Uncovering metabolic bottlenecks in genetic subtypes of lung cancer

Meet the Speakers:

M. Celeste Simon, PhD
Scientific Director and Investigator, Abramson Family Cancer Research Institute
Associate Director-Shared Resources, Abramson Cancer Center
Rubenstein Professor, Department of Cell and Developmental Biology
University of Pennsylvania Perelman School of Medicine

Thales Papagiannakopoulos, PhD
Assistant Professor
Department of Pathology
NYU School of Medicine

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?